Clinical Trials

CardiolRx™ is currently in clinical development for the treatment of heart disease, with two Phase II studies authorized by the FDA for recurrent pericarditis and acute myocarditis. A Phase I safety and pharmacokinetic study has been completed, showing that CardiolRx™ was safe and well tolerated at all dose levels, with no serious adverse events reported.

Answer last refreshed: 2026-10-02